Overview

Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Werewolf Therapeutics, Inc.

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab